Quick Facts

• Primary Use: Supports the temporary management of discomfort.
• Joint Conditions: Used in the care plan for joint-related concerns like osteoarthritis and rheumatoid arthritis.
• Symptom Relief: Provides help with pain and inflammation.

---

Flexilor is used for the symptomatic care of acute and chronic conditions characterized by discomfort and inflammation. Its primary role involves contributing to the care regimen for specific forms of arthritis, including osteoarthritis and rheumatoid arthritis.

This medication is also utilized to address symptoms related to acute musculoskeletal disorders and for the short-term management of mild to moderate post-operative discomfort. It supports the alleviation of pain, which may include joint pain and stiffness, facilitating better mobility within the context of the underlying condition. The use of Flexilor is intended to provide relief from these temporary symptoms to support the patient's overall comfort.

Flexilor's eligibility profile is based strictly on regulatory criteria, primarily applying to Adults for approved indications. Use is restricted or contraindicated in populations where risks are established or safety data is insufficient.

Contraindications (Must Not Use)

Flexilor is absolutely prohibited for patients with:

• Severe Organ Impairment: Severe hepatic impairment, severe renal impairment, or severe heart failure.
• Bleeding Disorders: Active or recurrent peptic ulceration/hemorrhage, history of GI bleeding related to prior NSAIDs, or other bleeding/coagulation disorders.
• Allergy: Hypersensitivity to Lornoxicam, excipients, or other NSAIDs (including aspirin).
• Late Pregnancy: Women in the third trimester of pregnancy.

Restricted and Non-Recommended Use

• Age Groups: The medicine is Not Recommended for use in children and adolescents under 18 years due to insufficient data. Use in older adults (ge 65 years) requires precaution and monitoring.
• Organ Impairment: Patients with mild to moderate renal or hepatic impairment may be eligible but require close clinical and laboratory monitoring.
• Pregnancy/Lactation: Use is Not Recommended during the first and second trimesters of pregnancy or while breastfeeding.

Interactions with other medicines and products

Flexilor (Lornoxicam) interaction information is classified based on official regulatory documentation.

The regulatory profile prohibits co-administration with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs) and Acetylsalicylic Acid (in analgesic doses) due to increased risk of adverse reactions. Consumption of alcohol is not recommended, as it increases the risk and severity of gastrointestinal bleeding.

A significant interaction domain involves pharmacokinetic alterations that affect drug clearance. Lornoxicam is documented to inhibit the renal clearance of substances such as Lithium and Methotrexate, which results in elevated serum concentrations of these drugs and heightened risk of toxicity. Concurrent administration with Cyclosporine may similarly increase its serum concentration, elevating the potential for nephrotoxicity. Cimetidine has been noted to increase Lornoxicam's own plasma concentration via documented effects on the CYP2C9 enzyme.

Another documented domain involves pharmacodynamic effects. Co-administration with anticoagulants or platelet aggregation inhibitors increases the risk and severity of bleeding and hemorrhage. Flexilor may also diminish the efficacy of certain medications, including Diuretics and ACE Inhibitors/Angiotensin Receptor Blockers (ARBs). This latter combination warrants specific caution in the elderly or those with renal impairment, due to potential for deteriorated renal function. Regulatory documents also note that taking Lornoxicam simultaneously with food reduces the rate of absorption, lowering the maximum plasma concentration (Cmax).

Modulation of Inflammatory Mediators via COX Inhibition

This domain involves the non-selective inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. By blocking the COX pathway, the drug prevents the synthesis of Prostaglandins (PGs) and other eicosanoids, which are key chemical messengers in physiological responses, including inflammatory processes. This molecular step modifies early molecular events that shape systemic physiological outcomes, resulting in the decreased excitability of peripheral nociceptors and suppression of local plasma extravasation.

Modulation of Central Nociceptive Pathways

This distinct mechanistic domain involves the drug's non-prostaglandin-mediated influence on the central nervous system. Lornoxicam engages mechanisms that enhance the availability and action of endogenous inhibitory peptides, such as Dynorphin and beta-Endorphin, in the spinal cord. This central action contributes to the modulation of afferent nociceptive signal propagation, which functionally interacts with the drug's peripheral enzymatic action.

Adjustment of Hypothalamic Thermoregulatory Setpoint

The inhibitory action of the drug also affects the central pathway governing core body temperature. By suppressing PGE2 production within the hypothalamus, the drug facilitates the reduction of the hypothalamic thermoregulatory setpoint.

Flexilor (Lornoxicam) is administered through two established methods: the oral route using film-coated tablets, and the parenteral route via intramuscular (IM) or intravenous (IV) injection. The tablets are primarily available in 4 mg and 8 mg strengths, while the injectable form is supplied as 8 mg of powder that requires reconstitution.

A general principle of Flexilor administration is to employ the lowest effective dose for the shortest possible duration. For oral dosing, such as in the symptomatic care of joint concerns, the total daily dose typically ranges from 8 mg to 16 mg but must not exceed the 16 mg maximum. This total amount is generally divided and administered in two or three separate doses per day.

Specific parameters apply to administration. Oral tablets should be taken before meals with water, as ingestion with food may impede the medicine's effect. The injectable powder must be immediately reconstituted with 2 ml of solvent before use. The injection technique dictates that IV administration must be completed over at least 15 seconds, while IM administration requires a minimum of 5 seconds.

Specific dosage limits apply to certain patient groups. For individuals with mild to moderate renal or hepatic impairment, the maximum daily dose is restricted to 12 mg. Furthermore, the medicine is not recommended for use in pediatric patients under the age of 18 due to a lack of sufficient data on safety and efficacy in this population.

Research evidence / Overview of studies for Flexilor

Evidence for Use in Acute Pain

The research on this medicine, exploring temporary, acute discomfort, consists primarily of controlled, randomized clinical trials and comprehensive meta-analyses. Research examined its use in studies involving adult populations reporting outcomes related to physical discomfort, such as following various surgical procedures, including dental, orthopedic, and gynecological surgery.

In these research scenarios, studies explored short-term symptom changes, monitoring patient-reported outcomes describing perceived discomfort, including measurements of symptom intensity and the amount of rescue pain medication used over defined time intervals. Findings describe patterns observed in the studies, mainly over very short time intervals, often within the first 24 hours post-procedure. Research exploring temporary physiological imbalance sometimes compared the observed patterns to those seen with placebo or other established medications.

Evidence for Use in Chronic Inflammatory Conditions

This area of research focused on conditions involving periods of heightened symptoms and functional limitations, with studies comparing the drug against placebo or other medications in the same class.

Symptomatic Relief of Osteoarthritis

Studies explored the use of the drug in adult patients with osteoarthritis (OA) of the hip or knee. These were often randomized trials that monitored outcomes reflecting daily functioning or activity level, alongside measurements of symptom intensity. Findings describe patterns observed in the studies related to physical discomfort, which were measured during the study period (e.g., 4 to 12 weeks). The research contributes to understanding symptom patterns in conditions marked by functional limitations.

Symptomatic Relief of Rheumatoid Arthritis

Research examined the drug in patients with active rheumatoid arthritis (RA). Studies monitored outcomes capturing phases of heightened symptom activity, such as joint tenderness and morning stiffness, in addition to overall global assessments reported by patients or the research staff. Findings describe patterns observed in the studies related to temporary symptomatic outcomes explored in conditions characterized by fluctuating manifestations.

Research Gaps and Uncertainty

Evidence highlights what is known—and what is still uncertain. The available evidence is concentrated on immediate postoperative pain models. Comparative evidence is lacking against all the newest therapeutic options for chronic conditions. Research provides context but not individual predictions, and does not determine whether an individual will respond similarly to the group patterns described in the studies.

Common questions about Flexilor (FAQ)

Q: How long does it usually take to notice any effect from Flexilor?

A: According to the official product information, the initial effect of Flexilor oral tablets is typically observed within 30 to 60 minutes of taking the dose. This time frame represents the onset of action, or how quickly the medicine begins working in the body.

Q: Is Flexilor known to cause weight gain or loss?

A: Regulatory documents list common side effects that affect the digestive system and appetite, such as anorexia (loss of appetite). However, weight gain or weight loss itself is not explicitly listed among the common or uncommon undesirable effects in the product's official safety profile.

Q: Is it okay to drive while taking Flexilor?

A: Official product information advises patients to exercise caution when performing tasks that require concentration, such as driving or operating machinery. This is because common side effects like dizziness and headache may occur. Patients are generally advised to note how the medicine affects their concentration before engaging in these activities.

Q: What happens if I stop taking Flexilor suddenly?

A: Regulatory guidelines emphasize the importance of using this medicine for the shortest possible duration. The official label does not specifically describe withdrawal symptoms from sudden cessation. Regulatory guidelines indicate that any adjustments to the treatment plan are managed by a healthcare professional.

Q: Is there a preferred time of day to take Flexilor?

A: There is no specific time of day required for dosing. However, the official product information states that oral tablets should be taken before meals with water. The daily dosage is generally intended to be administered in divided amounts.

Q: Does Flexilor interact with commonly used over-the-counter supplements?

A: The regulatory label lists documented interactions with specific prescribed drug classes and common over-the-counter products like other pain relievers. It does not provide a general list of all available over-the-counter supplements. Full disclosure of all concurrent therapies, including supplements, to a healthcare provider is a critical part of the safety assessment.

Q: Is it normal to feel a bit drowsy after starting Flexilor?

A: According to regulatory reports, dizziness is listed as a common side effect. Somnolence, which means drowsiness, is listed as an uncommon side effect, meaning it may affect up to 1 in 100 people who use the medicine. If this symptom is experienced, patients should review it with a healthcare professional.

Q: What information should I have ready when discussing Flexilor with a pharmacist?

A: When discussing this medicine, key patient information is required for the regulatory safety assessment. This includes any history of bleeding disorders, current organ impairment (heart, liver, or kidney issues), and a comprehensive list of all other prescription and non-prescription medicines being used.

Q: Does Flexilor have a 'Black Box' warning?

A: The term 'Black Box' is a specific regulatory warning used in the United States. While the specific label may vary by region, official documents globally contain serious warnings concerning the risk of gastrointestinal bleeding and potential cardiovascular events, which are known risks associated with the Non-Steroidal Anti-inflammatory Drug (NSAID) class.

Q: Is Flexilor habit-forming or addictive?

A: Flexilor is a Non-Steroidal Anti-inflammatory Drug (NSAID). This pharmacological class is not classified as a controlled substance and is not generally associated with a risk of habit formation or dependency.

Q: What should be done if a potential side effect of Flexilor occurs?

A: Official regulatory bodies strongly encourage patients to report any suspected side effects to a healthcare professional, such as a doctor or pharmacist. Adverse effects can also be reported directly to the national medicines regulatory authority in your country.

Q: How long does Flexilor stay in the body after the last dose?

A: Regulatory pharmacokinetic data indicate that Lornoxicam, the active component, has a mean elimination half-life of approximately 3 to 4 hours. This time period reflects the rate at which the concentration of the substance is reduced in the body as it is metabolized and eliminated.

Q: Can Flexilor interfere with birth control pills?

A: The regulatory product label does not contain a specific statement regarding an interaction with oral contraceptives. A healthcare professional is the appropriate source for guidance regarding the use of this medicine alongside any method of hormonal birth control.

Q: Do older people use Flexilor differently than younger adults?

A: For elderly patients (over 65) who have no organ impairment, a special dose change is generally not required. However, official warnings state the medicine should be used with precaution in this population, as older adults have a greater frequency and severity of adverse reactions, particularly relating to the digestive system.

Q: What ingredients are in Flexilor besides the main component?

A: The core active substance is Lornoxicam. Official documents for the dosage form also include a comprehensive list of inactive ingredients (excipients), which are the substances added to the tablet or solution to give it bulk, stability, or other necessary qualities.

Q: What if I'm already taking multiple medicines—is Flexilor still an option?

A: Flexilor is contraindicated (absolutely prohibited) with certain medicines and requires close monitoring when combined with numerous others, including those for blood pressure and blood clotting. A comprehensive review of all current medications by a healthcare provider is required as part of the safety assessment before the medicine is used.

Q: Does Flexilor affect blood pressure or heart rate?

A: Regulatory studies indicate that Flexilor has no effect on blood pressure in healthy individuals. However, palpitations (changes in heart rhythm) are listed as an uncommon side effect. Furthermore, as an NSAID, the medicine class carries a documented, serious risk of arterial thrombotic events.

Q: Can environmental factors, like heat, affect Flexilor's use?

A: The official storage guidelines are designed to maintain the drug's stability and quality, requiring that the medicine be stored below 30 C and protected from moisture. No specific patient guidance is provided regarding the effect of environmental heat on the drug’s action once it is taken.

Q: Why is my doctor asking me about my full medical history before prescribing Flexilor?

A: Doctors ask for a full history to identify conditions that are listed as contraindications (reasons why the medicine cannot be used). This screening is essential to avoid serious risks, such as prescribing to patients with severe organ impairment or a history of specific bleeding disorders.

Q: Are there any specific lifestyle changes that are recommended with Flexilor?

A: The official documents contain two key recommendations related to use: consumption of alcohol is strongly not recommended due to an increased risk of severe adverse effects, and oral tablets should be taken before meals to ensure optimal absorption.

Q: What should a patient know about Flexilor before a surgical procedure?

A: Flexilor reduces platelet aggregation and can prolong bleeding time. Due to this effect, caution is required when the medicine is used in patients with an increased bleeding tendency. Guidance from a healthcare professional regarding the specific timing of the last dose before any surgical procedure is required.

Q: Can men and women expect different outcomes from using Flexilor?

A: The regulatory summary of clinical trials does not explicitly state that expected outcomes differ significantly between men and women. The research evidence generally addresses outcomes across the overall study populations.

Q: What is the known range for when Flexilor's effect wears off?

A: The duration of the medicine's effect is closely related to its short elimination half-life, which is approximately 3 to 4 hours. This pharmacokinetic profile is the reason the total daily dose is typically divided and administered multiple times a day.

Storage Conditions

Flexilor (Lornoxicam) tablets and the powder for solution for injection must be stored at a temperature below 30 C. The medicine must not be refrigerated or frozen. Protection from moisture is required; therefore, the product should be kept in its original blister pack or outer carton until use.

Stability and Handling

For the powder for injection, the reconstituted solution should be used immediately. The maximum in-use stability after reconstitution is 24 hours at either 25 C (room temperature) or in a refrigerator (2 C–8 C). All forms of the medicine must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Flexilor must be disposed of in accordance with local requirements. Official regulatory guidance mandates that medicines must not be thrown away via wastewater or household waste to prevent environmental contamination.